A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis

Por: Szabados, BE, Rodriguez-Vida, A, Duran, I, Crabb, SJ, van der Heijden, MS, Pous, AF, Gravis, G, Herranz, UA, Protheroe, A, Ravaud, A, Maillet, D, Mendez, MJ, Suarez, C, Linch, M, Prendergast, A, Tyson, C, Mousa, K, Castellano, D and Powles, TB

---

Publicada: 1 nov 2020

---

---

Filiaciones:
Szabados, BE:
 Barts Canc Inst, Dept Med Oncol, London, England

Rodriguez-Vida, A:
 Hosp del Mar, Dept Med Oncol, Barcelona, Spain

Duran, I:
 Hosp Univ Virgen del Rocio, CSIC, Seville, Spain

 Univ Seville, Inst Biomed Sevilla, Seville, Spain

Crabb, SJ:
 Univ Southampton, Southampton Expt Canc Med Ctr, Southampton, Hants, England

van der Heijden, MS:
 Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

:
 Hosp Badalona Germans Trias & Pujol, Badalona Appl Res Grp Oncol B ARGO IGTP, Catalan Inst Oncol, Badalona, Spain

Gravis, G:
 Aix Marseille Univ, Med Oncol Dept, Nstitut Paoli Calmettes, Inserm,CNRS,CRCM, Marseille, France

Herranz, UA:
 Hosp Clin Univ Santiago, Med Oncol, Bordeaux, France

Protheroe, A:
 Churchill Hosp, Oncol, Oxford, England

Ravaud, A:
 Hop St Andre, Oncol, Bordeaux, France

Maillet, D:
 Hosp Lyon Sud, Oncol, Lyon, France

Mendez, MJ:
 Reina Sofia Univ Hosp, Oncol, Cordoba, Spain

Suarez, C:
 Vall dHebron Inst Oncol, Oncol, Barcelona, Spain

Linch, M:
 UCL, Inst Canc, Oncol, London, England

Prendergast, A:
 Barts Expt Canc Med Ctr, Barts Canc Inst, London, England

Tyson, C:
 Barts Expt Canc Med Ctr, Barts Canc Inst, London, England

Mousa, K:
 Barts Expt Canc Med Ctr, Barts Canc Inst, London, England

Castellano, D:
 Hosp 12 Octubre, Oncol, Madrid, Spain

Powles, TB:
 St Bartholomews Hosp, Oncol, London, England